• Leading the launch of Biocon Biosimilars with effective marketing strategies, ensuring rapid market penetration and adoption.• Expanding the market presence of Viatris and Biocon products into Unified Purchasing hospitals, increasing the company’s national footprint.• Effectively managing both company's diverse portfolios, ensuring optimal allocation of resources and maximizing return on investment.• Achieving significant revenue growth for the oncology franchise through successful sales strategies and market expansion.• Implementing cost-saving measures without compromising on quality, leading to improved profit margins. • Establishing collaborations with research institutions, hospitals, and key opinion leaders to educate junior oncologists for efficient practice. • Assembling and leading a high-performing sales and marketing teamMentoring and developing team members, fostering a culture of continuous learning and professional growth• Facilitating effective collaboration across different departments, such as P.V, regulatory, and commercial teams. • Building and maintaining strong relationships with key opinion leaders (KOLs) in oncology, enhancing the company’s influence and reputation.• Ensuring high levels of customer satisfaction through exceptional service, support, and educational initiatives for healthcare professionals.• Collaborating with patient advocacy groups to support patients and raise awareness about oncology products and treatments.• Leveraging market intelligence to anticipate industry trends and adapt strategies accordingly, maintaining a competitive edge.• Effectively managing devaluation challenges to minimize impact on the business.

- Drove Mylan brand's perception as a high-quality generic, securing market leadership in hospitals and clinics, with every chemotherapy prescription in Egypt including at least one Mylan product.- Spearheaded the launch of Epirubicin – Mylan®, which became a cornerstone product, contributing over 30% to oncology line sales.- Pioneered the introduction of Hertraz®, the first FDA-approved Trastuzumab Biosimilar, into the Egyptian market.- Launched Mylan-HEP C Sofosbuvir 400 mg, the first imported generic for HCV treatment in Egypt, which was later chosen as the drug of choice in the Presidential Campaign for HCV treatment.- Rebranded and relaunched the Mylan-Meda OTC and prescription line in 2017, achieving an expected turnover of 300 million EGP.- Maintained a stellar sales track record from 2015 to present, propelling the company to become one of the fastest-growing entities in the Egyptian pharmaceutical market, as per IMS data and reports.- Strategized and executed marketing plans for shipments of both locally produced and imported goods.- Managed demand and supply chains for distributors and retailers, ensuring efficient product availability.- Slashed expenses by over 30% through strategic budget allocation and optimal use of human resources.- Crafted and submitted successful tenders to Common Drug Review (CDR), public and private formularies, and institutional buying agencies, securing significant contracts such as the MOH portfolio for ICU lines in 2014.- Fostered strong relationships with key opinion leaders (KOLs) in major stakeholder groups, including MOH, health insurance, and university hospitals.- Recruited and developed a top-tier sales team through stringent practical and academic criteria, enhancing overall team quality.- Built a competitive and highly visible sales force, which became the foundation for numerous internal promotions within the sales and marketing departments.

- Increased area sales by over 40% since starting as an area sales manager in January 2013.- Built a sales team of more than 20 sales representatives and district managers.- Held patient access functions and responsibilities, fostering strong relations with KOLs in MOH and other reimbursement bodies, resulting in high sales volume and income.- Ensured effective product distribution in the area, including adequate stocking and coverage of all distribution channels, achieving high distribution efficacy and a low rate of expiry.- Secured a high share of voice, leading to a high market share and market leadership for several products in the ICU and Oncology Line.- Launched the GIT line from scratch, contributing 12% to area sales.- Supervised day-to-day sales activities.- Led through direction, motivation, coaching, skill development, product knowledge, industry knowledge, competitive knowledge, performance management, and company knowledge.- Planned and conducted regular sales meetings.- Worked with representatives in the field to coach and assess their skills.- Managed and controlled expenses to maximize return on investment.

- Promotion of Mylan's Oncology portfolio in Cairo & Giza Area - Distribution channel management - Area marketing activities - Area tenders management

- Promotion of Mylan's CCU portfolio in Cairo & Giza Area - Distribution channel management - Area marketing activities - Area tenders management

- Responsible for promoting products for psychiatrists, Neuro-surgeons and Neurologists like Pramipexole, Paroxitene , Memantine , Zopiclone and Prazolam at heliopolis and shubra areas

- Promotion of Cipla's Oncology portfolio which include the following products 1- Imatinib Methylate2- Doxorubicin 3- Docetaxel 4- Paclitaxel 5- Etoposide 6- Methotrexate 7- Mesna8- 5FU9- Gemcitabine

- Promoting Mostly products related to dermatologists , pediatricians , and ENT Doctors like Kerella, Emosoft , Gentazone and Ebastine- I was responsible for Mohandseen Area

- Performing Microscopic sample analysis and different bacterial cultures at the bacteriology department - I also worked in blood analysis, sampling, processing and various blood examination tests at the blood bank- has a good knowledge through practicing in different lab departments like Hematology, virology and immunology